ResMed Inc. (RMD)
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Stock Of The Day: Trading The Range In ResMed
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.
Here's Why ResMed (RMD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Davin Thillainathan - Goldman Sachs Lyanne Harrison - Bank of America Laura Sutcliffe - UBS Craig Wong-Pan - RBC Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Mathieu Chevrier - Citi David Low - JPMorgan Brett Fishbin - KeyBanc Capital Markets Operator Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call.
